Phuturdex › Diseases › Cardiovascular disease
Drugs in development · updated 30 October 2026
Cardiovascular disease: drugs in development
As of 30 October 2026 there are 74 active clinical trials (recruiting or ongoing, phases I–III) on 71 drugs for cardiovascular disease. 32 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Mosliciguat | III | 3 | NCT07816185 |
| Pelacarsen | III | 3 | NCT06813911 |
| AZD0780 | III | 2 | NCT07000357 |
| Olpasiran | III | 2 | NCT07136012 |
| Vicadrostat | III | 2 | NCT07064473 |
| [18F]FAPI-74 | III | 1 | NCT07613099 |
| Cagrilintide | III | 1 | NCT05669755 |
| EloralintideLY3841136 | III | 1 | NCT07900633 |
| Lepodisiran | III | 1 | NCT07613294 |
| Ralinepag | III | 1 | NCT03683186 |
| Retatrutide | III | 1 | NCT06383390 |
| Zilebesiran | III | 1 | NCT07181109 |
| 4D-310 | I–II | 2 | NCT05629559 |
| AC01 | II | 1 | NCT07584967 |
| Apelin | II | 1 | NCT03449251 |
| ATV-1601 | I–II | 1 | NCT07601425 |
| Clazakizumab | II | 1 | NCT07783802 |
| DII235 | II | 1 | NCT07235046 |
| L-NAME | II | 1 | NCT06424756 |
| MitoTempo | II | 1 | NCT06424756 |
| Nemtabrutinib | I–II | 1 | NCT03162536 |
| of 68Ga-NI-FAPI | I–II | 1 | NCT07464132 |
| Relaxin | II | 1 | NCT03449251 |
| RoxadustatEvrenzo® | I–II | 1 | NCT06903559 |
| SPC 2002 | II | 1 | NCT06826872 |
| SPC 2003 | II | 1 | NCT06826872 |
| SPC 2004 | II | 1 | NCT06826872 |
| Tempol | II | 1 | NCT06424756 |
| VERVE-102 | II | 1 | NCT07839936 |
| 68Ga-Galmydar | I | 1 | NCT07838649 |
| OriCAR-017 | I | 1 | NCT06271252 |
| STX-1150 | I | 1 | NCT07428473 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ColchicineColchicin, Lodoco® | III | 8 | NCT05633810 |
| EmpagliflozinJardiance | III | 4 | NCT07064473 |
| InclisiranLeqvio® | III | 4 | NCT06813911 |
| SemaglutideWegovy, Rybelsus | III | 4 | NCT05669755 |
| AspirinVazalore®, Durlaza® | III | 2 | NCT05633810 |
| SotagliflozinInpefa®, Zynquista® | III | 2 | NCT06217302 |
| ValsartanPrexxartan®, Diovan® | II–III | 2 | NCT04971720 |
| AllopurinolAloprim®, Lopurin® | III | 1 | NCT05943821 |
| AmbrisentanLetairis®, Ambrisentan Viatris (previously Ambrisentan Mylan)® | III | 1 | NCT07245680 |
| CarvedilolCoreg Cr®, Coreg® | III | 1 | NCT05931276 |
| EplerenoneEpleronone, Inspra® | II–III | 1 | NCT07892664 |
| FinerenoneBAY94-8862, Kerendia | III | 1 | NCT06082063 |
| IvabradineCorlanor®, Ivabradine Anpharm® | III | 1 | NCT05279651 |
| MetoprololLopressor®, Kapspargo Sprinkle® | III | 1 | NCT05931276 |
| Sacubitril∙ValsartanEntresto Pill, Neparvis® | II–III | 1 | NCT04971720 |
Sorted by most advanced phase and number of active trials. Showing 15 of 39 drugs.
All 71 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Multiple myeloma 272 drugs
- Ischemic stroke 94 drugs
- Heart failure 104 drugs
- Arterial hypertension 119 drugs
- Stroke 70 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Lymphoma 252 drugs
- Atrial fibrillation 32 drugs
- Non-Hodgkin lymphoma 269 drugs
- Hematologic neoplasm 216 drugs
- Pulmonary hypertension 38 drugs
- Neoplasm 671 drugs
Broader categories
- Vascular disease 16 drugs
- Nutritional and metabolic diseases 5 drugs
- Metabolic disease 30 drugs
- Heart disease 17 drugs
- Chronic arterial occlusive disease 3 drugs
- Glucose metabolism disease 12 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D002318 “Cardiovascular Diseases”.